Company: SINT
Filing Date: 2025-11-12
Form Type: 10-Q
Source: 0001493152-25-021930
Chunk: 3

Company: Sintx Technologies, Inc.
Filing Date: 2025-11-12
Form: 10-Q
Item: Item 8
Chunk 3
---
 the reported amounts of revenue and expenses during the period. Actual results could differ from
those estimates. As of September 30, 2025, the most significant estimate relates to derivative liabilities relating to common stock warrants.

    7

Reclassification

Certain
other prior period balances have been reclassified to conform to the current period presentation.

Liquidity
and capital resources 

The
condensed consolidated financial statements have been prepared assuming the Company will continue to operate as a going concern. To date,
the Company’s operations have been principally financed from proceeds from the issuance of preferred and common stock and, to a
lesser extent, cash generated from product sales. It is anticipated that the Company will continue to generate operating losses and use
cash in operations. The Company’s continuation as a going concern is dependent upon its ability to increase sales, decrease expenses
and raise additional funding. We continue to seek opportunities to raise additional funding through equity and/or debt financing. However,
such funding is not guaranteed and may not be available to the Company on favorable terms and may involve restrictive covenants. If the
Company is not able to obtain additional debt or equity financing, the impact on the Company will be material and adverse.

The
board of directors, together with management, remains focused on advancing the Company’s business strategy and focus. We are concentrating
our resources on high-growth areas within the healthcare sector where our proprietary materials and technologies—such as silicon
nitride—provide a distinct competitive advantage due to their unique strength, durability, and biocompatibility. Through this transformation,
as demonstrated by the recent FDA 510(k) clearance of our SiNAPTIC® Foot & Ankle Osteotomy Wedge System, our aim is to deliver
meaningful innovations to the medical community. By focusing on partnerships and collaborations with healthcare institutions and industry
leaders, SINTX is positioned to expand its footprint in the medical device sector and drive shareholder value through sustainable, high-impact
innovations.

On
August 8, 2024, the board of directors approved a plan to implement a Company-wide reduction in the workforce. This decision was part
of the Company’s ongoing strategic review of its operations aimed at improving operational efficiency and reducing costs.

On
August 12, 2024, the board of directors approved a plan to cease efforts to make the armor plant operational. This decision was made
to streamline operations and focus on core business areas that align with the Company’s long-term strategic goals. The armor plant